ClinicalTrials.gg
CompletedNCT02901366Updated Aug 21, 2018

Mass Balance Study of FYU-981

A Phase 2 interventional study of 14C-FYU-981 in Healthy Male Subjects, sponsored by Fuji Yakuhin Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-21.

Sponsored by Fuji Yakuhin Co., Ltd. · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

To assess the plasma pharmacokinetics, the routes extent of elimination, and the metabolites of FYU-981 after a single 1 mg oral dose of 14C-FYU-981 in healthy male subjects.

02

Conditions studied

  • Healthy Male Subjects

Keywords

  • Mass balance
03

In context

Lead sponsor

Fuji Yakuhin Co., Ltd. is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese healthy adult subjects
  • : >=18.5 and \<25.0

Exclusion criteria

Exclusion Criteria:

  • Subjects with any disease or any history of diseases that might be unsuitable for participation in the clinical study
  • Have participated in a [14C]-study within the last 12 months prior to dosing of the drug
  • Exposure to radiation for therapeutic or diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton) within the last 12 months prior to dosing of the investigational drug
  • Occupationally exposed worker
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    14C-FYU-981

    14C-FYU-981, (Oral single dosing)

    Drug: 14C-FYU-981

Interventions

  • Drug14C-FYU-981

    14C-FYU-981, (Oral single dosing)

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (Cmax: Maximum plasma concentration)

    Time frame: 168 hours

  2. Pharmacokinetics (AUC: Area under the plasma concentration-time curve)

    Time frame: 168 hours

  3. Pharmacokinetics (Tmax: Time to reach the peak plasma concentration)

    Time frame: 168 hours

  4. Pharmacokinetics (T1/2: Elimination half-life of plasma concentration)

    Time frame: 168 hours

  5. Pharmacokinetics (kel: Elimination rate constant)

    Time frame: 168 hours

  6. Pharmacokinetics (Vd/F: Distribution volume / Fraction of dose absorbed

    Time frame: 168 hours

  7. Pharmacokinetics (CLtot/F: Total clearance / Fraction of dose absorbed)

    Time frame: 168 hours

  8. Pharmacokinetics (MRT: Mean residence time)

    Time frame: 168 hours

  9. Pharmacokinetics (Ae(urine), Ae(feces) and Ae(air): Amount of radioactivity excreted in urine, feces, or air)

    Time frame: 168 hours or 72 hours (Ae(air))

  10. Pharmacokinetics (fe(urine) , fe(feces) and fe(air): Fraction of radioactivity excreted in urine, feces, or air)

    Time frame: 168 hours or 72 hours (Ae(air))

  11. Pharmacokinetics (Ae(total): Total amount of radioactivity excreted)

    Time frame: 168 hours

  12. Pharmacokinetics (fe(total): Total fraction of radioactivity excreted)

    Time frame: 168 hours

  13. Pharmacokinetics (Ae(urine + air): Amount of radioactivity excreted in urine and air)

    Time frame: 168 hours

  14. Pharmacokinetics (fe(urine + air): Fraction of radioactivity excreted in urine and air)

    Time frame: 168 hours

  15. Pharmacokinetics (Ratios of FYU-981 and its metabolites in plasma, urine and feces)

    Time frame: 168 hours

07

Study locations

1 site
  • Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Jan 2017 and a completion of Jul 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2016
First posted
Sep 15, 2016
Start
Sep 2016
Primary completionActual
Jan 2017
CompletionActual
Jul 2018
Last update
Aug 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02901366
Lead sponsor
Fuji Yakuhin Co., Ltd.
Collaborators
Mochida Pharmaceutical Company, Ltd.
Responsible party
Sponsor
First posted
Sep 15, 2016
Start date
Sep 2016
Primary completion
Jan 2017
Completion
Jul 2018
Last update
Aug 21, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion